SCHEMBL5144570

SCHEMBL5144570

CCOc1ccc(C=C(C(=O)Nc2cccc(C(F)(F)F)c2)C(=O)Nc2cccc(C(F)(F)F)c2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.59
MAPT P10636 5/20 0.59
GAA P10253 4/20 0.59
NPY1R P25929 1/20 0.59
NPSR1 Q6W5P4 3/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
POLB P06746 1/20 0.54
ALOX12 P18054 1/20 0.54
RXFP1 Q9HBX9 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
HPGD P15428 1/20 0.49
HTT P42858 1/20 0.49
GPR35 Q9HC97 1/20 0.49
LMNA P02545 3/20 0.48
XBP1 P17861 1/20 0.48
IDH1 O75874 1/20 0.48
ERBB2 P04626 1/20 0.47
NPC1 O15118 1/20 0.47
MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5144537 0.87 GAA (0.61) ALDH1A1MAPTGAAMEN1KMT2A
SCHEMBL5144571 0.85 THRB (0.50) ALDH1A1MAPTGAANPSR1MEN1
SCHEMBL5142746 0.84 MAPT (0.54) ALDH1A1MAPTGAANPSR1MEN1
SCHEMBL5142386 0.83 MAPT (0.54) ALDH1A1MAPTGAANPSR1MEN1
SCHEMBL5142732 0.82 MAPT (0.62) ALDH1A1MAPTGAANPSR1MEN1
SCHEMBL5145891 0.81 MAPT (0.55) ALDH1A1MAPTGAANPSR1MEN1
SCHEMBL5142680 0.81 MAPT (0.54) ALDH1A1MAPTGAANPSR1MEN1
SCHEMBL5141404 0.81 SMN1; SMN2 (0.50) ALDH1A1MAPTGAANPSR1MEN1
SCHEMBL5149441 0.81 TP53 (0.55) ALDH1A1MAPTGAANPSR1MEN1
SCHEMBL5142352 0.81 ERBB2 (0.58) ALDH1A1MAPTGAANPSR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043076-A1 Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis CYTOVIA, INC. 2007-02-22 US claimed
WO-2005037196-A2 SUBSTITUTED 2-ARYLMETHYLENE-N-ARYL-N'-ARYL-MALONAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS CYTOVIA, INC. (US) 2005-04-28 WO claimed
US-7291618-B2 Therapeutic compounds PFIZER INC (US) 2007-11-06 US disclosed
US-20070043076-A1 Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis CYTOVIA, INC. 2007-02-22 US disclosed
US-20050256310-A1 Therapeutic compounds PFIZER INC 2005-11-17 US disclosed
WO-2005037196-A2 SUBSTITUTED 2-ARYLMETHYLENE-N-ARYL-N'-ARYL-MALONAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS CYTOVIA, INC. (US) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256310-A1 Therapeutic compounds REN, SLC5A1, SLC5A2 ALDH1A1 1222/4885MAPT 4050/4885GAA 869/4885
US-20070043076-A1 Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis CASP14, CASP2, CASP3 ALDH1A1 952/4885MAPT 4733/4885GAA 835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.